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Activated Cdc42-associated kinase or ACK, is a non-receptor tyrosine kinase 
and an effector protein for the small G protein Cdc42. A substantial body of 
evidence has accumulated in the past few years heavily implicating ACK as a 
driver of oncogenic processes. Concomitantly, more is also being revealed 
regarding the signalling pathways involving ACK and molecular details of its 
modes of action. Some details are also available regarding the regulatory 
mechanisms of this kinase, including activation and regulation of its catalytic 
activity, however a full understanding of these aspects remains elusive. This 
review considers the current knowledge base concerning ACK and 
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The tyrosine kinase ACK (also known as ACK1 and TNK2) was identified over 
25 years ago as the first effector protein described for Cdc42, a member of 
the Rho family of small G proteins. ACK belongs to a family of non-receptor 
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tyrosine kinases (NRTKs) and has been implicated in diverse cellular 
functions, including survival, proliferation and migration. In humans there are 
three ACK-related proteins, ACK (the product of TNK2), TNK1 (TNK1) and 
Mig-6 (ERRFI1) (Figure 1) and homologues have been identified in mouse, 
Drosophila melanogaster and Caenorhabditis elegans. ACK and TNK1 are 
members of the same family of non-receptor tyrosine kinases based on the 
similarity of their kinase domains, while the adapter protein Mig-6 shares 
Cdc42/Rac and EGFR binding regions with ACK. Splice variants of both ACK 
and TNK1 have been reported. ACK2, a C-terminally truncated form of ACK 
was first identified in bovine brain (1), while Kos1, a C-terminally truncated 
version of TNK1 has been isolated from mouse stem cells (2).  
 
Clues to the normal physiological roles of the ACK related proteins have come 
from studies in model organisms. Drosophila possess two ACK related 
proteins: DACK and DRP2. DACK is more similar in primary sequence to 
ACK, however it lacks a Cdc42/Rac interacting motif (CRIB). DPR2 has less 
similarity at the primary sequence level to ACK but does contain a CRIB motif, 
making it difficult to assign orthologues between humans and mice. DACK is 
critical for sperm formation (3) and has been shown to function in dorsal 
closure during embryogenesis (4). Although DACK lacks a CRIB motif, its 
functional similarity to ACK is supported by rescue experiments where mouse 
ACK could rescue sterility caused by a mutation in DACK, whereas DPR2 
could not (3). Many interacting proteins are also shared between ACK and 
DACK, further suggesting functional homology. Interestingly DACK has been 
shown to suppress apoptosis downstream of EGFR and to also function in 
regulating EGFR signalling via endocytosis, suggesting functional 
conservation with the mammalian system (see below) (5).  
 
Additional work in Caenorhabditis elegans has studied the role of ARK-1 in 
vulval development, a process regulated through the RTK/Ras/MAPK 
signalling pathway. ARK-1 (Ack-related tyrosine kinase) was shown to be a 
novel inhibitor of let-23 EGFR signalling (6) paralleling its role in higher 
eukaryotes (see below).  
 
All ACK family members have been implicated in cancer progression. ACK 
gene amplification and protein overexpression correlates with poor prognosis 
in a wide variety of cancers: somatic mutations have also been identified in 
ACK, which act as cancer drivers and have been shown to possess increased 
kinase activity (7-9). In contrast, TNK1 is thought to act as a tumour 
suppressor since TNK1 knockout mice develop spontaneous lymphomas and 
carcinomas upon ageing (10). Similarly, Mig-6 knockout mice develop tumors 
in various tissues (11-15).  
 
Given the prominence of ACK in the initiation and maintenance of various 
cancer types it is timely to reflect on our current understanding of the 
regulation of this kinase, its impact on cellular signalling pathways and the 
progress that has been made in targeting this specific protein for therapeutic 




The activation and regulation of ACK 
 
ACK comprises 1038 amino acids and is made up of multiple domains, as 
befits a signalling protein (Figure 1A). The N-terminus of ACK comprises a 
sterile alpha motif (SAM) domain, nuclear export signal (NES), tyrosine kinase 
domain, Src homology-3 (SH3) domain and a Cdc42/Rac-interactive binding 
(CRIB) motif. The proline-rich C-terminus of ACK includes a clathrin binding 
region, an epidermal growth factor receptor-binding domain (EBD, also 
referred to as the MHR, Mig6-homology region) and a ubiquitin association 
domain (UBA). In fact the domain organization of ACK is unique amongst 
mammalian tyrosine kinases with the SH3 domain C-terminal to the kinase 
domain (16) and the presence of a CRIB motif.  
 
ACK has been reported to be stimulated downstream of various major classes 
of cell surface receptors: RTKs, GPCRs and Integrins (Figure 2). Despite this, 
the specific details of how this activation occurs remain elusive. ACK has 
been shown to respond to a wide variety of extracellular stimuli including 
growth factors such as EGF, heregulin, PDGF, Gas6, IGF, Insulin and 
neutrophins (17-19), suggesting activation downstream of RTKs. The 
interaction between ACK and RTKs is often direct but ACK has also been 
shown to associate with adaptor proteins including Grb2, Nck (17) and HSH2 
(20) facilitating indirect RTK association (21). Apart from RTKs, ACK 
responds to cell adhesion via integrin stimulation (17,22,23) and also sits 
downstream of GPCRs for example muscarinic receptors (24). It has been 
suggested that the involvement of Src (see below) in the activation of ACK 
facilitates this wide-ranging response. 
 
Perhaps understandably, most of the efforts directed towards investigating the 
activity and regulation of ACK have concentrated on its kinase activity. Initial 
investigations using purified protein reported that ACK undergoes 
autophosphorylation on Tyr284 in the activation loop but this only modestly 
enhances kinase activity (16). The activity of ACK towards test substrates was 
also assessed to be much lower than other NRTKs. Interestingly binding of 
ligands to neither the SH3 domain nor the CRIB region activated ACK. Initial 
structural studies confirmed the early biochemical data. The ACK kinase 
domain adopts a classic kinase fold and comparison of the non-
phosphorylated and phosphorylated forms showed few differences, 
corroborating the kinase activity data and suggesting that ACK is 
constitutively active (25). The ACK kinase domain is closest in structure to the 
EGRF kinase domain, which equally does not require phosphorylation for 
activity.  
 
Later work added detail to the regulation of ACK kinase activity (26). Analysis 
of the ACK dimers observed in the crystal lattices formed by ACK revealed 
that active ACK adopts a symmetrical dimer. This is now thought to be a 
major mechanism behind the activation of ACK, in a manner analogous to the 
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autoactivation of EGFR via dimerization. Furthermore experimental 
dimerization, mediated by the addition of a GST tag, increased the activity of 
ACK constructs significantly. These data fitted nicely with previous work 
indicating that the SAM domain at the N-terminus of ACK was required for 
activation of ACK (17,27). SAM domains are well characterized as mediating 
dimerization (28) and the SAM domain of ACK is implicated in its self-
association (27). 
 
Further work shed light on the different intramolecular interactions in ACK that 
likely regulate its kinase activity (Figure 1B). The SH3 domain appears to bind 
a proline rich sequence (PRR) C-terminal to the EBD (17,26). The structure of 
the SH3 revealed it is actually rather unusual, with a non-canonical peptide-
binding site (26). This probably explains the failure of early studies to see any 
effects with representative peptide substrates (16).  The SH3-PRR interaction 
is thought to orientate the EBD permitting inhibitory interactions with the 
kinase domain (8). Binding of the EBD to RTKs relieves this inhibition and 
frees the kinase domain. Dimerization of ACK via the SAM domain orientates 
the free kinase domain to allow autoactivation (26). Slight variations around 
this theme have also been proposed (29). 
 
Although these studies do not include a role for phosphorylation in the 
activation of ACK, ACK had been shown to interact with, and be a substrate 
for, Src and Hck (16). Later work in cells identified Src as the major kinase 
acting at ACK Tyr284 (30). Thus it appears that ACK activity can be increased 
by phosphorylation but this is probably mediated by Src or a Src family kinase. 
In summary, it appears that autoactivation by dimerization plays the major role 
in ACK activation but phosphorylation at Tyr284 by Src contributes either to 
full activation or represents an alternative mechanism to regulate ACK.  
 
Despite its initial discovery as a binding partner for Cdc42, the role of Cdc42 
and its binding to the CRIB region in ACK activation remain elusive. Initial 
studies with purified protein ruled out a direct role for Cdc42 in the activation 
of ACK kinase activity (16). Studies using an ACK mutant (H464D) incapable 
of binding Cdc42 have shown inconsistent results, with both a severe 
reduction in phosphorylation reported (17) and no changes observed (30). As 
small G proteins often act to localize their effectors to membranes, it is 
possible that the interaction between ACK and Cdc42 may be required for 
correct localization in the cell that then facilitates activation. In fact cellular 
localization, by whatever means, appears crucial for the activity of ACK. The 
SAM domain has been postulated as a membrane association domain and 
deletion of the SAM domain in ACK perturbs phosphorylation of the kinase 
(17). Whilst localization to membranes may be important for ACK activity, 
ACK is increasingly being shown to have crucial functions in the nucleus and 
the Cdc42 interaction may facilitate directing ACK to the nucleus, although no 




The nuclear functions of ACK: ACK is an epigenetic modifier and 
transcriptional activator  
 
ACK shuttles between the cytoplasm and nucleus transducing extracellular 
signals to both cytosolic and nuclear effectors. The androgen receptor (AR), 
which plays a pivotal role in the normal growth and development of the 
prostate gland as well as in prostate carcinogenesis, is a major nuclear target 
for ACK and is heavily implicated in prostate cancer. The AR binds to its 
natural ligand, an androgenic hormone, in the cytoplasm, leading to 
dimerization and subsequent translocation to the nucleus. Upon binding of the 
AR to androgen response elements (AREs) in the promoter and enhancer 
regions of target genes, the AR-ligand complex recruits additional machinery 
to initiate transcription (32). Uncontrolled activation of the AR is a prerequisite 
for the progression of prostate cancer to the hormone refractory stage also 
known as castration resistant prostate cancer (CRPC). In this stage the 
androgen receptor is transcriptionally active even at the low levels of 
circulating androgen resulting from androgen deprivation therapy (ADT), the 
primary treatment for patients presenting with metastatic prostate cancer (32). 
Numerous mechanisms have been reported to explain how prostate cancer 
cells become androgen independent. These include amplification or mutation 
of AR as well as altered expression of AR co-regulatory proteins. In addition, it 
has become apparent over the years that growth factors, for example IGF1, 
may activate the AR in a ligand independent manner, through activation of 
receptor tyrosine kinase pathways (33).  
 
More recently, ACK was shown to bind and directly phosphorylate the 
androgen receptor on two sites, Tyr267 and Tyr363, both located in the 
transactivation domain (Figures 2 and 3) (34). Phosphorylation at these sites 
is required for optimal AR-dependent transcription and when mutated at 
Tyr267, the AR fails to promote castration-resistant growth of prostate 
xenograft tumours (34). Further analysis revealed a distinct transcriptional 
program directed by pTyr267-AR (35). pTyr267-AR binds ATM (Ataxia 
telangiectasia mutated) enhancer elements and upregulates transcription of 
ATM (Ataxia telangiectasia mutated), a key mediator of DNA repair. The AR 
recruits ACK to the nucleus as part of a larger AR transcriptional complex, 
upregulating transcription of androgen-dependent genes including ATM. As a 
DNA damage sensor, ATM is activated by double strand breaks (DSB) and 
initiates a signalling cascade to block cell cycle progression to promote DNA 
repair, ensuring genetic integrity and cell survival (36). In the absence of DNA 
repair pathways, cells that acquire DNA damage undergo apoptosis. The ACK 
mediated upregulation of ATM in prostate cancer cells increases resistance to 
DNA-damage inducing agents including, most notably, radiation therapy (35). 
Human prostate tissue microarray analysis showed that the levels of pTyr284-
ACK and pTyr267-AR are elevated in prostate cancer cells and this correlated 
with disease progression to the CRPC stage (34). These data describe a 
signalling nexus involving ACK, the AR and ATM, which mediates prostate 
cancer progression (Figure 3).  
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As well as regulating transcriptional activity of the AR, ACK also promotes 
chromatin alterations to drive AR expression and subsequent CRPC 
progression (Figure 3). ACK directly phosphorylates Histone H4 on Tyr88 
upstream of the AR transcriptional start site (37). pTyr88-H4 marks are 
recognized by the WDR5/MLL2 chromatin remodelling complex, which 
deposits transcriptionally activating H3K4-trimethylation marks. Via direct 
phosphorylation of Histone H4, ACK reprograms the AR locus to upregulate 
AR mRNA and subsequent protein levels in the androgen-deficient 
environment of CRPC. Tissue microarray analysis revealed H3K4me3 and AR 
levels increase with disease progression to the CRPC stage (37).  
 
Combined, these studies have established a crucial role of ACK in the 
progression of CRPC, providing an additional mechanism by which prostate 
cancer cells can adapt to androgen deficiency. Deposition of pTyr88-H4 
marks by ACK prompts enhanced AR expression to compensate for low 
androgen levels, while direct phosphorylation of the AR results in a distinct 
gene expression signature contributing to CRPC. Another feedback loop may 
also exist to upregulate ACK in a low androgen environment; following 
androgen deprivation, androgen-sensitive LAPC4 cells showed an 
upregulation of ACK levels (37). The signalling nexus involving the AR and 
ACK is therefore well characterized and describes crucial nuclear functions for 
ACK in prostate cancer progression (Figure 3). 
 
ACK can also function as an epigenetic regulator in breast cancer, by directly 
phosphorylating KDM3A4, a histone demethylase that removes H3K9 marks, 
facilitating upregulation of oestrogen receptor (ER) target genes. Tyrosine 
phosphorylation of KDM3A promotes demethylation at ACK/ER bound 
promoters resulting in transcriptional upregulation of HOXA1, a critical ER-
regulated mammary tumour oncogene (38). In fact ACK activation promotes 
ER activity even in the presence of tamoxifen (38), suggesting that the 
epigenetic functions of ACK in ER-positive breast cancers may underpin the 
mechanisms by which cells acquire tamoxifen resistance.  
 
ACK has also been reported to directly target other transcription factors. 
STATs (signal transducers and activators of transcription) are cytoplasmic 
transcription factors and ACK promotes the phosphorylation of STAT1 and 
STAT3 on Tyr701 and Tyr705 respectively (39). Phosphorylation of STATs at 
this site is the major signal for their activation, resulting in nuclear 
accumulation and induction of STAT-dependent gene expression. 
Immunohistochemical staining of primary lung adenocarcinoma cells revealed 
a positive correlation between the levels of ACK and pSTAT3 (39).  
 
Another mechanism through which ACK regulates transcriptional activity is by 
modulating the nuclear import of certain transcription factors. For example, 
ACK modulates early activation events in T-cells via the indirect regulation of 
transcription factors (40). ACK targets the adaptor protein SLP-76, to 
modulate nuclear import of certain transcription factors. ACK binds SLP-76 via 
its SAM domain and phosphorylates proximal tyrosine residues. SLP-76 has 
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been reported to bind RanGAP1 at the nuclear pore complex and regulate 
nuclear transport of transcription factors (41). ACK expression increased 
NFAT/AP1 promoter activity and enhanced calcium influx in T-cells in 
response to stimulation, processes dependent on SLP-76 (40).  
 
Taken together these data suggest that ACK functions at may different levels 
and via several mechanisms, to alter the transcriptional activity of a variety of 
different transcription factors either indirectly or directly.  
 
ACK modulates the PI3-Kinase signalling pathway at multiple nodes 
 
The PI3-Kinase pathway is one of the most frequently activated pathways in 
cancer (Figure 4). Class 1a PI3-Kinases exist as heterodimers composed of a 
catalytic p110 subunit and regulatory p85 subunit. PI3-Kinase is recruited to 
activated RTKs by binding to pTyr residues in the C-terminal tail of receptors. 
The binding of p85 SH2 domains to these pTyr residues relieves the 
regulatory inhibition on the p110 subunit activating the lipid kinase activity. 
Catalytically active p110 phosphorylates PIP2 resulting in accumulation of 
PIP3 in the membrane. Akt, the key downstream signalling component of the 
PI3-Kinase pathway, is recruited to the membrane by binding PIP3 via its PH 
domain. Once at the membrane Akt is activated by phosphorylation at Thr308 
and Ser473, by PDK1 and PDK2/mTOR respectively, and can then 
phosphorylate its substrates to transduce various growth and survival signals. 
ACK has been described as the third PDK as it directly phosphorylates Akt on 
Tyr176 enhancing its membrane recruitment (Figure 2) (42). pTyr176 Akt 
preferentially binds to phosphatidic acid in the membrane dispensing with one 
of the PIP3-dependent Akt activation steps (Figure 4) (9). Importantly, 
pTyr176-Akt and pTyr284-ACK were found to localize to the nucleus where 
they act to repress FoxO-responsive apoptotic gene expression.  
 
Instances of breast and prostate cancer that exhibit Akt activation whilst 
retaining normal PTEN and PI3-Kinase activity have remained confounding, 
however direct activation of Akt by ACK may resolve this perplexity (43-45). 
An ACK transgenic mouse model displayed Akt activation and developed 
prostatic intraepithelial neoplasia (PIN). In addition, increased pTyr284-ACK 
and pTyr176-Akt levels were observed in progressive stages of breast cancer 
and inversely correlated with patient survival (9). These data highlight the role 
of ACK/PI3-Kinase signalling in breast and prostate cancer.  
 
Work from our own group has recently uncovered a new role for ACK in the 
modulation of the PI3-Kinase pathway via a direct interaction with the PI3-
Kinase regulatory subunits (Figures 2 and 4). ACK interacts with all five 
isoforms of the p85 regulatory subunit and directly phosphorylates four of 
them on a conserved tyrosine residue located in the iSH2 domain, equivalent 
to Tyr607 p85α (46). Phosphorylation at Tyr607 was shown to promote 
proliferation but not via an increase in PI3-Kinase signalling. Instead 
phosphorylation at this site led to increased stability of the regulatory subunits, 
via evasion of the ubiquitin-proteasome degradative pathway, so regulating 
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the cellular level of p110-free p85 subunits. p110-independent functions of 
p85 predominate in the nucleus and the ACK/p85 complex was detected in 
nuclear enriched fractions only. The phosphorylated p85 isoforms form homo- 
and hetero-dimers mediated by the C-terminal regions of p85. These newly 
identified C-terminally mediated dimers can form between any isoforms of the 
PI3-Kinase regulatory subunits, including the shorter splice variants of p85α; 
p50α and p55α but preferential binding to p85β was observed, suggesting 
p85β homodimers or heterodimers are favoured. C-terminally mediated 
p50α/p85β dimers were predominantly found in the nuclear enriched fractions, 
whereas standard N-terminally mediated p85α/p85β dimers were seen in 
cytoplasmic fractions. Therefore, via direct phosphorylation of the PI3-Kinase 
regulatory subunits, ACK promotes stabilization and formation of nuclear C-
terminally mediated dimeric p85. The predicted configuration of these nuclear 
dimers suggests that SH3 or RhoGAP domain activities could drive the pro-
proliferative functions of p85 phosphodimers.   
 
Nuclear functions for p110-free p85 have been documented, predominantly in 
stress response pathways. Under conditions of stress, p53 mediates cell 
growth arrest and apoptosis, a process controlled by lysine acetylation, which 
leads to p53 activation. p85α has a role in mediating p53 acetylation at 
Lys370, regulating its promoter-specific transactivation (47). X-box binding 
protein-1 (XBP-1) is one of the main regulators of the unfolded protein 
response and both p85α and p85β have been found to interact with XBP-1 
and upregulate its nuclear translocation (48). Nuclear functions for p50α and 
p55α have also been described. p50α and p55α were found to localize, bind 
chromatin and regulate transcription of a subset of genes that overlapped with 
STAT3 controlled genes (49). Whether a dimeric configuration of the PI3-
Kinase regulatory subunits influences this growing list of nuclear functions 
remains to be determined. Changes in cellular levels of regulatory subunit can 
result in substantial changes in PI3-Kinase signalling (50). By direct 
phosphorylation, ACK may specifically target and stabilize one isoform of the 
PI3-Kinase regulatory subunit to further modify and direct PI3-Kinase 
signalling by perturbing the p85 isoform balance, so driving Cdc42/ACK 
mediated oncogenesis. N-terminal domain interactions have also been 
implicated in mediating p85 dimerization (51). These dimers have been 
reported to bind and directly enhance PTEN lipid phosphatase activity (51,52). 
Whether ACK mediated C-terminal dimers of p85 also retain this stimulatory 
activity on PTEN is unknown, but may account for the decrease in PIP3 levels 
seen upon exogenous ACK expression (46).  
 
The complexity of the PI3-Kinase/AKT/mTOR signalling network involves 
numerous feedback loops and extensive cross talk with other signalling 
pathways. We, and others, have demonstrated that ACK targets the PI3-
Kinase pathway at multiple nodes providing additional layers of regulation. For 
example, exogenous ACK expression was shown to suppress EGF-induced 
stimulation of PI3-Kinase signalling as measured by the levels of PIP3 in the 
cell (46), suggesting that ACK reduces PIP3 signalling direct from the 
membrane. This seems discordant with a pro-proliferative function of ACK. 
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However this may be circumvented via direct phosphorylation and activation 
of Akt, independent of PIP3, and formation of nuclear dimeric p85. 
Compensatory mechanisms in signalling pathways often provide opportunities 
for circumventing inhibitory effects (53). With such extensive regulation, the 
ACK/PI3-Kinase signalling network may underpin resistance to PI3-Kinase 
inhibitors and help drive ACK mediated oncogenesis (Figure 4) (54).  
 
The cytoplasmic functions of ACK 
 
Although many functions of ACK are localized to the nucleus, cytoplasmic 
roles and alternative layers of regulation for ACK have also been described. 
ACK forms a complex with HSP90 (Heat-shock protein 90), a chaperone 
protein that regulates the molecular structure and function of many signalling 
proteins, particularly kinases. HSP90 is required for the kinase activity of ACK 
and its association with Cdc42 (55). HSP90 has been shown to be required 
for ACK kinase activity towards STAT1 and STAT3 (39) as well as WWox 
(56). WWox (WW domain containing oxidoreductase) is a tumour suppressor 
protein that plays a role in DNA damage response pathways and genomic 
stability. Phosphorylation at Tyr33 activates WWox, enhancing its interactions 
with downstream binding partners, including p53. Following UV irradiation, 
pTyr33-WWox binds and stabilizes pSer46-p53 inducing apoptosis (57). A 
significant loss or reduction of WWox gene expression is observed in many 
cancer types, namely breast (58), prostate (59) and pancreatic (60). ACK 
phosphorylates WWox on Tyr287 targeting it for ubiquitination and 
subsequent degradation (Figure 2). Elevated levels of pTyr284-ACK and 
decreased WWox levels were observed in primary androgen-independent 
prostate tumours but not in benign prostate cells. It is becoming apparent that 
ACK often functions to regulate the stability of its substrates, as is the case for 
WWox and the PI3-Kinase regulatory subunits. By regulating the stability and 
degradation of distinct signalling proteins ACK can shift the equilibrium of 
these pathways to promote tumorigenesis as exemplified by ACK-mediated 
promotion of prostate cancer progression by negative regulation of the levels 
of proapoptotic Wwox.   
 
ACK regulates receptor endocytosis and vesicular trafficking  
 
ACK interacts with several components of vesicle dynamics including AP2, 
sorting nexin 9 (SNX9), synaptojanin-1 and clathrin (Figure 5). AP2 is an 
adaptor protein and is involved in receptor-mediated endocytosis (61), while 
SNX9 is an endocytic accessory protein involved in clathrin-mediated 
endocytosis (62). SNX9 is also described as a multifunctional scaffold due to 
its emerging role in membrane remodeling and trafficking (63). ACK binds and 
phosphorylates SNX9 on Tyr287 in mammalian cells. In doing so, ACK is able 
to regulate SNX9 endocytic functions. In fact, studies using ACK2 highlighted 
a role of SNX9 in EGF induced EGFR degradation, with cells expressing 
ACK2 and SNX9 displaying EGFR degradation following EGF treatment (64). 
SNX9 links synaptojanin-1 to ACK coated vesicles, further implicating the 
involvement of ACK in vesicle dynamics involving AP2, synaptojanin-1 and 
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clathrin (62). ACK also binds to clathrin heavy chains and is involved in 
clathrin-mediated endocytosis (61). Exogenous ACK expression induced 
reorganization of clathrin from a widespread distribution including distinct 
perinuclear and vesicular puncta to colocalize with ACK in large vesicular 
structures, which was associated with the loss of transferrin uptake. The over 
expression of ACK also inhibited clathrin-mediated endocytosis by functionally 
sequestering clathrin (61).  
 
Endocytosis and trafficking of the Epidermal Growth Factor Receptor (EGFR) 
is crucial for the regulation of EGFR signalling. EGF binding results in EGFR 
dimerization, autophosphorylation and activation, initiating a signalling 
network mediating cell survival, proliferation and differentiation. Following 
activation, the EGFR is endocytosed from the cell surface and undergoes a 
regulated sorting process (Figure 5). Internalized EGFR is targeted to early 
endosomes for either membrane recycling or trafficked through the 
endosomal pathway to lysosomes for degradation (65).  
 
In accordance with its role in clathrin-coated vesicle endocytosis, ACK 
interacts with the EGFR in response to EGF stimulation and plays a role in its 
degradation (66). The interaction with the EGFR is mediated by the region 
towards the C-terminus of ACK, designated the EBD (Figure 1). The 
interaction between ACK and EGFR is also dependent upon the kinase 
activity and tyrosine phosphorylation of the receptor (66). It has been 
postulated that the EGFR/ACK interaction is indirect and requires an SH3-
domain containing EGFR adaptor protein (66). Grb2 is an adaptor protein that 
has been described for its role in EGF-stimulated EGFR internalization (21,67) 
and is a known partner of ACK (68). Grb2 is required for the interaction of 
ACK with other RTKs, such as Axl family kinases and insulin receptor-like 
kinases, LTK (leukocyte tyrosine kinase) and ALK (anaplastic lymphoma 
kinase) (21). ACK also regulates the degradation of these RTKs in response 
to stimuli, such as Axl receptor degradation following Gas6 treatment, 
however the adaptor protein mediating the interaction between ACK and the 
EGFR remains to be formally confirmed (21,66). 
  
Mig-6, which is highly related to ACK, has also been identified as a negative 
regulator of EGF signalling. Studies have revealed that Mig-6 inhibits the 
catalytic activity of EGFR as well as directing EGFR endocytosis. Mig-6 knock 
out mice displayed hyperactivation of endogenous EGFR (69). Most recently, 
Mig-6 has been shown to regulate the ubiquitination and degradation of EGFR 
mutants in lung adenocarcinomas cells (70). Mig-6 deficiency accelerated the 
initiation and progression of mutant EGFR-driven tumourigenesis but in this 
case Mig-6 did not promote degradation of mutant EGFR (15). Thus, via their 
conserved EBD domain, both Mig-6 and ACK play roles in regulating EGFR 
endocytosis, trafficking and degradation. The tight interplay of both ACK and 
Mig-6 in coordinating EGFR signalling is potentially driven by competition for 
binding to the EGFR by their respective EBDs.   
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EGF stimulation also induces ACK degradation in parallel with EGFR 
degradation. The tight correlation between the degradation of ACK and the 
EGFR suggested co-transportation of the ACK/EGFR complex (71). 
Colocalization of ACK and EGFR on EEA-1 positive vesicles following EGF 
stimulation has been observed (66) and the EGFR/ACK complex is finally co-
transported to lysosomes for degradation (Figure 5) (71).  
 
The EGFR is ubiquitinated in response to EGF by recruitment of the E3 ligase 
Cbl (72). Ubiquitinated EGFR is transported through the endosome pathway 
to lysosomes for degradation, while non-ubiquitinated EGFR is recycled back 
to the membrane (72,73). ACK is ubiquitinated and degraded along with the 
EGFR in response to EGF stimulation and this is mediated by the Nedd4 
proteins. Both Nedd4-1 (71) and Nedd4-2 (74) have been identified as E3 
ligases targeting ACK but with contrasting outcomes. Co-expression with 
Nedd4-1 resulted in ubiquitination levels of ACK 10-fold higher than with 
Nedd4-2 and Nedd4-1 catalysed ubiquitination of ACK was required for EGF-
induced lysosomal degradation of the EGFR. In contrast Nedd4-2 had a 
minimal effect (71) but was reported to trigger ACK turnover via proteasomal 
degradation (74). It is likely that both Nedd4 proteins target ACK for 
ubiquitination but the functional differences remain to be fully defined.  
 
ACK has also been identified as a ubiquitin-binding protein, a property 
attributed to its UBA domain (Figure 1). Overexpression of a UBA deletion 
mutant of ACK displayed increased ubiquitination itself, attributed to enhanced 
binding to Nedd4-1. In contrast deletion of the ACK SAM domain reduced 
ubiquitination by Nedd4-1. It is speculated that the lysine-rich SAM domain 
contains ubiquitination target sites for Nedd4-1. When ubiquitinated, the UBA 
domain may interact with the SAM domain altering the conformation of ACK, 
blocking access to Nedd4-1 and preventing excessive ubiquitination (71). 
ACK ubiquitination therefore, may lead to conformation changes and regulate 
the catalytic activity of the kinase itself as well as EGFR endosomal trafficking.  
 
The interaction between ACK and EGFR has been reported to occur at a late 
stage of EGFR internalization, following 30-60 minutes of EGF stimulation. 
These data suggest that the interaction might not occur on the plasma 
membrane (66). Alternatively, Grb2 has been shown to link ACK to multiple 
other receptor tyrosine kinases and ACK kinase activation has also been 
reported within 5 minutes of EGF treatment, suggesting ACK might be 
activated at an earlier stage in the process (21,67). It is possible that the 
EGFR/ACK complex forms on endosomes and the ubiquitination of ACK via 
Nedd4-1 may serve as a sorting signal for trafficking the EGFR/ACK complex 
to lysosomes (71). In fact, over expression of ACK led to the retention of the 
EGFR on early endosomes, inhibiting translocation to MVBs (75). EGFR 
signalling is not restricted to the plasma membrane and activated EGFR can 
continue to signal from endosomes. For example, endocytosis of EGFR is 
required for the sustained activation of Akt but not for activation of the MAPK 
pathway. Endocytosis of the EGFR is therefore crucial in maintaining normal 
signalling kinetics (65). In fact endosomal EGFR signalling is sufficient to 
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support cell survival and proliferation (76). Regulation of receptor endocytosis 
by ACK therefore functions to modulate distinct signalling networks. ACK 
senses EGF signalling and downregulates the EGFR receptor preventing 
excessive signalling from the membrane. ACK is recruited to the EGFR on 
endosomes and regulates endocytic trafficking, with ubiquitination serving as 
the sorting signal, which directs EGFR signalling. Ultimately, the role ACK 
plays in clathrin-mediated receptor endocytosis is key to regulating the normal 
kinetics of signalling pathways (Figure 5).  
 
ACK regulates pathways involved in cell migration 
 
Cell migration is orchestrated by the dynamic assembly and disassembly of 
actin filaments. Actin polymerization at the cell leading edge, in response to 
specific external cues, drives the plasma membrane forward using extensions 
known as filopodia and lamellipodia. Cell-cell and cell-extracellular matrix 
(ECM) adhesions are also rapidly modified to allow for cell movement through 
tissues. Formation of the appropriate actin network involves both nucleation of 
new filaments and polymerization of branched filaments by an activated 
Arp2/3 complex, driving filopodia and lamellipodia formation respectively. The 
Arp2/3 complex is activated by members of the Wiskott-Aldrich Syndrome 
Protein (WASP) family with WASP itself being one of the main activators (77). 
The VCA domain of WASP activates the Arp2/3 complex: the WASP V region 
interacts with actin monomers and couples them to Arp2/3, which associates 
with the CA region (78). Efficient migration and invasion requires coordination 
of these dynamic cellular processes and hence these pathways are tightly 
controlled. 
 
Members of the Rho family of small GTPases, including Cdc42, play essential 
roles in coordination of pathways mediating cell migration both under normal 
physiological conditions and in disease (Figure 2) (79,80). In melanoma cells 
a signal transduction complex incorporating active Cdc42, ACK and 
phosphorylated p130Cas mediates cytoskeletal rearrangements permitting cell 
invasion (22). p130Cas is an adaptor protein involved in cell motility and 
integrin signalling (81) and has been implicated as a downstream target for 
ACK (22). ACK also binds and directly phosphorylates the Arp2/3 activator 
WASP on two distinct residues: Tyr256 and Ser242. In fact phosphorylation at 
WASP Ser242 was the first evidence of the dual kinase activity of ACK (82). 
Phosphorylation of WASP by ACK in vitro is enhanced by the presence of 
Cdc42 or PIP2 and phosphorylation of WASP Tyr256 by Src-family kinases 
has been reported to enhance the ability of WASP to promote actin 
polymerization (83,84). Phosphorylation at both WASP Ser242 and WASP 
Tyr256 has been shown to stimulate actin polymerization in vitro (82). Ser242 
is located in the Cdc42 binding region (CRIB region), which is bound to the 
VCA domain in the autoinhibited state. It is likely that phosphorylation at this 
site triggers a conformational change, releasing the VCA domain in WASP 
and allowing for activation of the Arp2/3 complex. Additional regulation of 
Arp2/3 dynamics is controlled by ACK via a direct interaction with cortactin, an 
Arp2/3 regulatory protein. ACK directly phosphorylates cortactin on Tyr421, 
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Tyr466 and Tyr482. Actin polymerization is vital in driving membrane 
dynamics necessary for receptor internalization and in fact cortactin localizes 
with ACK to vesicles containing ligand-bound EGFR. Cortactin forms a link 
between actin polymerization and EGFR internalization and degradation (85). 
The data described here highlight the involvement of ACK in multiple signal 
transduction complexes, coordinating actin dynamics necessary for cell 
migration and receptor downregulation. Signalling through these complexes 
may underpin the oncogenic properties of ACK in promoting cellular migration 
and invasion. Moreover, loss of ACK suppresses normal membrane dynamics 




Therapeutic AttACK in cancer 
 
There are many lines of evidence suggesting that ACK plays an important role 
in tumourgenesis, several of which have already been discussed. The gene 
encoding ACK is located within a small amplicon on chromosome 3q and 
copy number gain as well as overexpression of ACK mRNA is frequently 
observed in advanced stage primary tumours as well as metastatic tumours, 
including lung, prostate, breast, pancreatic, hepatocellular and gastric 
carcinomas (Figure 6) (86). In fact although mutated variants of ACK are 
found in many forms of cancer, gene amplification (of up to 29%) seems to be 
the major change found for ACK in most cancers (Figure 6) (87,88). Despite 
this, mutated variants of ACK have also been reported but at lower levels (1-
5% of cancers). A genomic study, seeking to identify cancer ‘driver’ mutations 
within the protein kinase family, identified four such mutations in ACK. In fact 
ACK was placed 28th out of 518 kinases ranked in order of carrying at least 
one driver mutation (7). Furthermore, the somatic missense mutations 
identified fall in several distinct domains of ACK and have been subsequently 
shown to stimulate ACK activity (7-9). These include two mutations (R34L and 
R99Q) in the N-terminus identified in lung and ovarian carcinoma, 
respectively; a mutation in the catalytic domain (E346K) identified in ovarian 
endometrioid carcinoma and a mutation (M409I) in the SH3 domain identified 
in lung adenoacarcinoma.  More direct evidence supporting an oncogenic role 
for ACK came from studies in which LNCaP cells, stably expressing wild type 
(wt), constitutive active (ca) or kinase dead (kd) ACK, were injected 
subcutaneously into male nude mice. In contrast to wtACK or kdACK LNCaP 
cells which were poorly tumourigenic, LNCaP cells expressing caACK 
exhibited robust tumour formation in 23 days (56). In addition, transgenic mice 
expressing ACK, specifically in the prostate, developed prostatic intraepithelial 
hyperplasia by 22 weeks and mPINs by 44 weeks, further supporting a key 
role for ACK in tumour initiation (9). In a large-scale RNAi screen, ACK was 
also identified as one of 73 kinases that regulated cell survival and apoptosis 
in the HeLa cervical carcinoma cell line (89).  
 
Due to the important role for ACK in numerous cancers it is not surprising that 
several efforts have been undertaken to identify small molecule inhibitors of 
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this tyrosine kinase. One of the first ACK inhibitors to be identified was 4-
amino-5,6-biaryl-furo[2,3-d]pyrimidine, an ATP mimetic which inhibits ACK 
with an IC50 of 0.024 µM and shows selectivity over Lck (90). This inhibitor, 
more commonly known as AIM-100, has since been profiled against a panel 
of 30 serine/threonine and tyrosine kinases and showed >15-fold selectivity 
for all of the kinases tested, with the other major hits being Lyn, Lck, Abl1 and 
Btk with IC50s of 0.35, 0.43, 0.71 and 0.87 µM respectively (35). Given its 
relative selectivity over other kinase inhibitors reported to target ACK, such as 
Dasatanib and Bosutinib, AIM-100 has been used extensively in in vitro 
studies to help reveal the role ACK plays in promoting the proliferation and 
survival of cancer cells. For example, increasing concentrations of AIM-100 
inhibited Tyr267 phosphorylation on the AR and decreased the growth of two 
prostate cancer cell lines, LNCaP and LAPC4 (91). A similar effect was 
observed in pancreatic cells where AIM-100 abrogated ACK Tyr284 
phosphorylation leading to a concomitant reduction in AKT Tyr176 
phosphorylation and decreased cell growth, with GI50 values reported to be 
approximately 7-8 µM (60). 
 
Whilst AIM-100 and other early probes are effective in vitro tool compounds 
they had poor pharmacokinetic (PK) properties, which prevented them from 
being utilized in vivo. More recently Jiao et al. reported the identification of a 
series of imidazo [1,5-a] pyrazine-derived molecules that are potent, selective 
inhibitors of ACK and display good in vivo PK properties, making them useful 





Studies to date have hugely expanded our understanding of the regulation 
and signalling functions of ACK in cells. However, despite the preclinical 
evidence suggesting ACK plays a role in the growth of many tumours and 
data from the clinic suggesting that expression levels of activated ACK 
correlate with disease progression, no ACK inhibitors have yet progressed 
into the clinic. This is possibly due to the plethora of roles reported for ACK, 
and lack of clarity around its primary function. The availability of more 
selective ACK inhibitors and the advancement of CRISPR technology to 
knockdown ACK will inevitably help uncover further new functions and aid 
understanding of the many different roles ACK plays in the cell. In particular, it 
is essential to understand how aberrant activation of ACK, through 
amplification, overexpression or constitutive activation, can lead to enhanced 
tumourigenesis and the development of resistance to standards of care such 
as radiation therapy. Further advances should establish ACK as an important 




Importance of the field: ACK is a non-receptor tyrosine kinase with a central 
role in a wide range of signalling pathways, controlling diverse processes 
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such as cell growth, cell migration and vesicular trafficking. A large body of 
data has emerged recently to suggest that ACK plays an important role in 
tumourigenesis with gene amplification, overexpression and activation being 
associated with many different cancers. This makes ACK an attractive 
therapeutic target, especially in prostate cancer, where its influence is 
particularly well-documented. 
 
Current thinking: Despite its widely documented roles, the precise 
mechanisms by which ACK is activated, either as an effector protein of Cdc42 
or downstream of receptor tyrosine kinases remains unclear. Several 
substrates of ACK have been identified and the molecular mechanisms by 
which these phosphorylation events impact on downstream signalling 
pathways are beginning to be uncovered. In particular, the emerging role for 
ACK as a regulator in the nucleus has been revealed, with ACK repurposing 
well-known proteins to new functions, regulating transcription factors and even 
acting as an epigenetic regulator controlling gene transcription through 
phosphorylation of proteins involved in chromatin remodelling.  
 
Future directions: However, we are still a long way from understanding the 
full extent of ACK’s roles in cell signalling pathways and how, when 
dysregulated, this can lead to disease pathologies such as cancer. In order to 
be able to develop safe and effective therapies, a full understanding of the 
complex signalling networks orchestrated by ACK will be imperative. Some 
studies also indicate possible kinase-independent functions for ACK and this 
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Figure 1: Domain architecture of ACK related proteins and regulation of 
ACK 
(A) Domain structure of ACK related proteins. SAM: Sterila Alpha Motif, 
NES: Nuclear Export Signal, SH3: Src Homology Domain 3, CRIB: Cdc42/Rac 
Interactive binding motif, Clath: Clathrin binding region, EBD: EGFR binding 
domain, UBA: Ubiquitin association region, PEST: PEST sequence, 14-3-3- 
BD: 14-3-3 binding domain, AH Region: ACK homology region. Numbers 
indicate amino acid positions. (B) Activation of ACK.  Interactions between 
the PRR (proline rich region) within the C-terminus of the EBD region and the 
SH3 domain orientate the EBD permitting inhibitory interactions with the 
kinase domain. ACK is activated by dimerization mediated via the SAM 
domain. Full activation may require Src-mediated phosphorylation at position 
Tyr284 within the kinase domain activation loop.  Membrane localization could 
be provided by interactions between the EBD and RTKs, the CRIB region and 
Cdc42 or the SAM domain with the membrane directly. Phosphorylation sites 
are shown as orange circles. 
 
Figure 2: ACK regulates multiple targets 
Cartoon summarizing the main targets of ACK kinase activity and the cellular 
processes they are involved in regulating. Phosphorylation sites are shown as 
orange circles. ACK: Activated Cdc42-Associated Kinase, Akt: AKR mouse 
thymoma, AR: Androgen Receptor, GPCR: G-Protein Coupled Receptor, RTK: 
Receptor Tyrosine Kinase, WASP, Wiskott-Aldrich Syndrome Protein, Wwox: 
WW Domain Containing Oxidoreductase, PI3K: Phosphatidylinositol-3-
Kinase.  
 
Figure 3: ACK modulates Androgen receptor signalling to drive 
castration resistant prostate cancer growth 
Cartoon summarizing physiological AR activity and the known points of 
influence of ACK on both AR expression levels and activity. Phosphorylation 
sites are shown as orange circles. ACK: Activated Cdc42-associated kinase, 
AR: Androgen receptor, ARE: Androgen response elements, ATM: Ataxia 
telangiectasia mutated, DHT: Dihydrotestosterone, HSP90: Heat Shock 
Protein 90, H4: Histone H4, Pol II: Polymerase II, T: Testosterone, RTK: 
Receptor Tyrosine kinase 
 
Figure 4: ACK regulation of the PI3K signalling pathway 
Cartoon summarizing the points of influence of ACK on components of the 
PI3-Kinase signalling pathway. Phosphorylation sites are shown as orange 
circles. ACK: Activated Cdc42-associated Kinase, Akt: AKR mouse thymoma, 
FoxO transcription factor, AP2: adaptor protein 2 complex, PA: phosphatidic 
acid, PDK1: Phosphoinositide-dependent kinase-1, PDK2: Phosphoinositide-
dependent kinase 2, PIP2: Phosphatidylinositol 4,5-bisphosphate, PIP3: 
Phosphatidylinositol (3,4,5)-trisphosphate, PTEN: Phosphatase and Tensin 
homologue, SNX9: Sorting Nexin 9, Ub: ubiquitin 
 
	 25	
Figure 5: ACK regulation of receptor endocytosis 
Cartoon showing the main stages of receptor mediated endocytosis, the 
sorting of the EGFR after stimulation and the main points of influence of ACK 
in the process. ACK: Activated Cdc42-associated kinase, AP2: Adaptor 
protein 2, EGF: Epidermal Growth factor, EGFR: Epidermal Growth Factor 
Receptor, Nedd-4; Neural precursor cell expressed developmentally down-
regulated protein 4, SNX9: sorting nexin 9, Ub: ubiquitin. 
 
Figure 6: ACK in cancer 
 
The frequency of changes in ACK by mutation, fusion, amplification, deep 
deletion or multiple alterations displayed across all types of cancers. Data 
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